Medical devices, healthcare technology and the business of care
PMA SUPPLEMENT · P910018/S041

LIPOSORBER LA-15 System

Kaneka Pharma America Corp. · Decision date Mar 30, 2026

FDA DECISIONP910018/S041

What did the FDA approve?

FDA records P910018/S041 as a supplement to PMA P910018, with the supplement type “Real-Time Process”. The recorded decision is approval, dated Mar 30, 2026.

FDA approval order statement

Approval for a change in the supplier of the lubricant, calcium stearate, added to the polyethylene resin used in the manufacture of the hollow fiber of the device.
Regulatory pathway
PMA supplement
Supplement type
Real-Time Process
Clinical specialty
Gastroenterology, Urology
Decision date
Mar 30, 2026
FDA change category
Labeling Change - Indications/instructions/shelf life/tradename

FDA source record

Regulatory record facts

Identifier
P910018/S041
Regulatory pathway
PMA supplement
Product code
MMY
Decision code
APPR
Decision date
Mar 30, 2026
Source update
Nov 9, 2026
Original record
Open FDA source record

About this medical device

FDA device category: Lipoprotein, low density, removal.

Product code
MMY
FDA device class
3

Review the original FDA PMA listing for the original approval scope and linked supplements.

FDA decision timeline

  1. P910018/S041 received

    Application receipt date recorded by FDA.

  2. P910018/S041 · FDA decision

    Real-Time Process

  3. P910018/S042 · Related supplement

    LIPOSORBER LA-15 System

Timeline entries are records held by MedtechLedger for P910018. View FDA’s full supplement list.

Related devices and submissions

Same PMA: P910018

Product / regulatory recordCompanyPathwayDecision dateSource
Kaneka Pharma America Corp.PMA supplementJun 16, 2026FDA

Explore the linked device profile

Regulatory context

A PMA supplement records a change to a device with an existing premarket approval. The supplement’s approval applies to the change described in that submission.

FDA describes the real-time supplement process as a review route for minor changes to a device, including certain design, software, sterilization or labeling changes.

Read our guide to FDA clearance and approval · FDA’s explanation of this pathway

Manufacturer intelligence

Kaneka Pharma America Corp.

Headquarters
Not reported
Brand website
Not reported
FDA applicant address
546 Fifth Ave., 21st Floor, New York, NY, 10036

Sources and methodology

FDA fields and approval-order wording are presented as source information. MedtechLedger explanations are identified separately and describe the scope of the recorded decision. Indications from an original PMA are historical unless confirmed against subsequent labeling and supplements.

How we use FDA records